The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Paĭchadze A.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Minzdrava Rossii

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Ustinova T.V.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kornietskaia A.L.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Karpenko E.Yu.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Koroleva L.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Fedenko A.A.

Department of Proctological Oncology, N.N. Blokhin Russian Cancer Reseach Center, Russian Academy of Medical Sciences, Moscow

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Observation of the high efficiency of therapy for metastatic colorectal cancer

Authors:

Paĭchadze A.A., Bolotina L.V., Ustinova T.V., Kornietskaia A.L., Karpenko E.Yu., Koroleva L.A., Fedenko A.A., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2019;8(5): 366‑369

DOI: 10.17116/onkolog20198051366

Views: 732

Downloaded: 12

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Paĭchadze AA, Bolotina LV, Ustinova TV, et al. . Observation of the high efficiency of therapy for metastatic colorectal cancer. P.A. Herzen Journal of Oncology. 2019;8(5):366‑369. (In Russ.)
https://doi.org/10.17116/onkolog20198051366

МСФ на ЯМ
Close metadata
Recommended articles:
Colo­rectal cancer and gut microbiota. P.A. Herzen Journal of Onco­logy. 2024;(2):60-66
Unco­ntrolled inhi­bition of checkpoints. P.A. Herzen Journal of Onco­logy. 2024;(2):67-73
Modern treatment methods for patients with liver meta­stases from uveal mela­noma. P.A. Herzen Journal of Onco­logy. 2024;(2):74-84
Correction of anemia and mito­chondrial dysfunction by iron citrate «Sintezit» during neoadjuvant chemotherapy for colo­rectal cancer and lymphoproliferative diso­rders. Russian Journal of Evidence-Based Gastroenterology. 2024;(1):21-31
Gona­dotropin-releasing hormone agonists as a chance for motherhood in the future. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):30-36
Drug therapy for loca­lly adva­nced and meta­static non-small cell lung cancer with MET muta­tion: indi­rect comparison. Medi­cal Technologies. Asse­ssment and Choice. 2024;(3):82-92
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2024;(10):7-20
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
New pathogenic treatments for myasthenia gravis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):31-38

Today, understanding the molecular mechanisms involved in the activation of signaling pathways that initiate intracellular proliferation, adhesion, invasion, and angiogenesis has led to the design and widespread clinical introduction of targeted drugs that enhance the efficiency of treatment and minimize its toxicity for other organs and tissues. The possibility of using targeted therapy is assuming a particular importance in previously treated patients. The present-day experience with Regorafenib allows the latter to be considered as an effective agent in the treatment of patients with advanced colorectal cancer.

Keywords:

chemotherapy
targeted therapy
regorafenib
generalized colorectal cancer

Authors:

Paĭchadze A.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Minzdrava Rossii

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Ustinova T.V.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kornietskaia A.L.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Karpenko E.Yu.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Koroleva L.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Fedenko A.A.

Department of Proctological Oncology, N.N. Blokhin Russian Cancer Reseach Center, Russian Academy of Medical Sciences, Moscow

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

List of references:

  1. Kaprin AD, Starinskii VV, Petrova GV, eds. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2017. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018. (In Russ.)
  2. Kaprin AD, Starinskii VV, Petrova GV, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018. (In Russ.)
  3. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422. https://doi.org/10.1093/annonc/mdw235
  4. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl.3):iii1-iii9. https://doi.org/10.1093/annonc/mdu260
  5. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer. 2002;38(Suppl.2):15-20. https://doi.org/10.1016/s0959-8049(01)00415-4
  6. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, et al. Phase II trial of infusional fluorouracil, irinotecan and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453-459. https://doi.org/10.1200/JCO.2009.24.8252
  7. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245-255. https://doi.org/10.1002/ijc.25864
  8. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. https://doi.org/10.1016/S0140-6736(12)61900-X
  9. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomized, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619-629. https://doi.org/10.1016/S1470-2045(15)70156-7
  10. Artamonova EV. New possibilitiesof therapy of intensively pretreated metastatic colorectal cancer patients. Meditsinskii sovet. 2016;(10):24-32. (In Russ.)
  11. Sekacheva MI, Bagmet NN. Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice. Sovremennaya onkologiya. 2016;18(3):43-47. (In Russ.)

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.